High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated...

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacology

Background:

• Cytochrome P450 enzyme 3A4 (CYP3A4) significantly influences drug-drug interactions (DDIs) through metabolic induction.
• CYP3A4-mediated DDIs can lead to reduced drug efficacy or increased toxicity, posing challenges in clinical development.

Purpose of the Study:

• To develop and validate a Physiologically Based Pharmacokinetic (PBPK) model for predicting CYP3A4 induction-mediated DDIs.
• To assess the model's predictive performance in the early stages of clinical drug development.

Main Methods:

• Developed and validated a PBPK model for rifampicin, a known CYP3A4 inducer, using human pharmacokinetic data.
• Constructed and validated PBPK models for 'victim' drugs.
• Evaluated the PBPK-DDI model's predictive accuracy for area under the curve (AUC) and maximum concentration (Cmax) ratios against empirical data using established criteria.

Main Results:

• The rifampicin PBPK model accurately simulated human pharmacokinetic profiles.
• The PBPK-DDI model achieved high predictive accuracy for AUC ratios (89% within 0.5-2 fold, 79% meeting Guest criteria) and Cmax ratios (93% within acceptable range).
• The PBPK-DDI model demonstrated superior performance compared to static models in predicting CYP3A4 induction DDIs.

Conclusions:

• The developed PBPK-DDI model serves as a reliable tool for predicting CYP3A4 induction-mediated DDIs.
• The model's high predictive accuracy supports its utility in drug development and clinical pharmacology.
• Future refinements hold potential to further enhance the model's predictive capabilities.